drugset
drugset / Trial / NCT05875259

A Clinical Trial Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult Subjects

NCT05875259 ↗

Phase 1 Completed 36 enrolled Boryung Pharmaceutical Co., Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetic interaction and safety between BR1019-1 and BR1019-2 in healthy adult subjects.

Timeline

Start
2023-05-13
Primary completion
2023-06-29
Completion
2023-06-29

Drugs

EvaluationDrugModalityDoseRoute
Subject BR1019-1 Unknown — —
Subject BR1019-2 Unknown — —

Indications

hypertensive disorder type 2 diabetes mellitus